Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Novartis’ Radioligand Therapy, More Meds Inch Closer to Japan Approval with Panel OK
A Japanese health ministry panel on August 22 recommended regulatory approval for Novartis’ radioligand therapy lutetium vipivotide tetraxetan (177Lu) along with a batch of other new medicines and indications. First biosimilars for three compounds are also in line for approval.…
To read the full story
Related Article
- J&J Files for 4-Week SC Dosing of Rybrevant in Japan
October 28, 2025
- Japan Hands Out Orphan Tags to 10 Compounds
September 30, 2025
- Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster
September 22, 2025
- J&J’s Subcutaneous Rybrevant Faces Delay in Japan Approval Process
September 17, 2025
- Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
August 12, 2025
- Japan Nears Approval for 1st Biosimilars of Actemra, Simponi, and Ranmark
August 12, 2025
- Nippon Kayaku Files Nuvation-Partnered ROS1 Inhibitor in Japan
March 5, 2025
- Boehringer Files Zongertinib in Japan for HER2 Lung Cancer
February 19, 2025
- Nihon Servier Files Glioma Drug Vorasidenib in Japan
December 25, 2024
- Alfresa Files ARS’ Epinephrine Nasal Spray in Japan
December 2, 2024
- Vectibix Plus Lumakras Filed for Colorectal Cancer in Japan
November 11, 2024
- Tecentriq Filed for Rare Nasal Lymphoma in Japan: Chugai
November 1, 2024
REGULATORY
- Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
September 17, 2026
- Ueno Retained as Health Minister in Takaichi Cabinet Reshuffle
September 17, 2026
- Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
September 17, 2026
- Japan Finalizes Framework for OTC-Like Drug Charge Ahead of March Rollout
September 17, 2026
- Shionogi ADHD App to Go Out-of-Pocket after 2 Treatment Cycles
September 17, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…